Human TNF-α Antibody

Anti-human TNF-α antibody - Human IgA2 (low effector functions)

Binding of anti-TNF-α mAb

Anti-hTNF-α-hIgA2 is an Adalimumab biosimilar with an IgA2 isotype. Adalimumab is a therapeutic antibody that targets tumor necrosis factor-alpha (TNF-α) and blocks the interaction of soluble and membrane-bound TNF-α with its receptors TNFR1 and TNFR2. Adalimumab is FDA-approved for the treatment of rheumatoid arthritis, Crohn's disease, and psoriasis.

 More details

Anti-hTNF-α-hIgA2 comprises the variable region of Adalimumab and an IgA2 constant region for low effector functions. 

This antibody can be used together with HEK-Blue™ TNF-α cells for screening and neutralization assays to block recombinant human TNF-α-induced signaling (see figure).
 

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• Absence of endotoxins determined by the EndotoxDetect assay

More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see in the 'upon request' section). 
InvivoGen’s products are for research use only, and not for clinical or veterinary use.

 Learn more about antibody isotype effector functions by reading our flyer on Clinically relevant monoclonal antibodies.

Figures

Increasing concentrations of Anti-hTNF-α-IgA2 were incubated for 30 minutes with the recombinant cytokine hTNF-α (30 pg/ml) prior to the addition of HEK-Blue™ TNF-α cells. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are shown in percentage (%) of neutralization.

Specifications

Application: Neutralization assay, ELISA, Fc interaction studies

Isotype:  Human IgA2, kappa

Recommended isotype control: Human IgA2

Target: Human TNF-α

Species reactivity: Human

Clone: Adalimumab, Anti-TNF-alpha

Sterility: 0.2 µm filtration

Source: CHO cells 

Production: Animal-free

Purification: Protein A

Molecular weight: 

Physical form: Lyophilized

Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative: Azide-free

Reconstitution buffer: Sterile water (not provided)

Purity: ≥ 95 %

Quality control: Each lot is functionally tested and validated

Contents

Anti-hTNF-α-hIgA2 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

• htnfa-mab7: 100 µg
• htnfa-mab7-3: 3 x 100 µg 

Product is shipped at room temperature.

Upon receipt, store lyophilized antibody at -20°C.

Details

Tumor necrosis factor-alpha (TNF-α) is a pleiotropic cytokine involved in necrotic and apoptotic cell death, cellular differentiation, inflammation, and regulation of immune cell activity [1]. Notably, deregulated TNF-α production has been implicated in a variety of conditions, including autoimmune and inflammatory diseases [1]. TNF-α is mainly produced by activated monocytes, macrophages, and T cells. It is first synthesized as a membrane-bound molecule (tmTNF) that forms a compact homotrimer through non-covalent interactions. The trimeric membrane-bound form is cleaved by tumor necrosis factor-alpha converting enzyme (TACE) releasing the soluble trimer (sTNF) [2].

Both the membrane-bound and soluble TNF-α bind homotrimeric transmembrane receptors, TNFR1 or TNFR2, triggering signaling pathways that involve TRADD, TRAF2, and RIP, and leading to the activation of NF-κB and MAPK pathways [2]. Importantly, membrane-bound TNF can also mediate a reverse "outside-to-inside" signaling, although this mechanism remains to be fully elucidated [2]. 

Adalimumab is a therapeutic, fully human IgG1 monoclonal antibody (mAb) that targets and blocks the interaction of both tmTNF-α and sTNF-α with TNFR1 and TNFR2, thereby downregulating the inflammatory responses. Adalimumab is used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis [3].

References:

1. Steeland S., et al. 2018. A new venue of TNF targeting. Int. J. Mol. Sci. 19:1442.
2. Shealy D.J. & Visvanathan S. 2008. Anti-TNF antibodies: lessons from the past, roadmap for the future. Therapeutic Antibodies (book). 101-129.
3. FDA website, visited Dec 2024: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf